Omeros (OMER): H.C. Wainwright Sees 128% Upside Potential and Justifies This With a Potential Approval of Narsoplimab

Omeros Corporation (OMER) is focusing on the approval of Narsoplimab. In the first quarter, the company took strategic steps accordingly. A potential FDA decision for its main product Narsoplimab is expected on September 25. The drug, a MASP-2 inhibitor, is currently being evaluated for the treatment of TA-TMA, a life-threatening complication following stem cell transplants. Narsoplimab has proven promising in improving treatment outcomes and reducing mortality in this high-risk group. The company has refiled its Biologics License Application (BLA)...